Sanjivani Paranteral Ltd

Sanjivani Paranteral Fund Raise

Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.

Sanjivani Paranteral Annual General Meeting

Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.

Sanjivani Paranteral Annual Report

Sanjivani Paranteral Limited has filed its Annual Report for the financial year 2025-26 as required under SEBI regulations. The document details the company's annual performance.

Sanjivani Paranteral Annual General Meeting

Sanjivani Paranteral shareholders approved the issuance of 5,00,000 convertible warrants to promoters on a preferential basis. A material related party transaction with subsidiary SPL Infusion was also cleared.

Sanjivani Paranteral Results Update

Sanjivani Paranteral reported Q1 FY27 results, with total income of ₹23.99 Crore and a net profit of ₹2.49 Crore. The company demonstrated strong year-on-year growth across key metrics.

Sanjivani Paranteral Investor Presentation: Key Takeaways

Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.

Call

Guides 110% growth

Sanjivani Paranteral Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 47.1% YoY

Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.

Key figure

Net profit ₹2.5 Cr · +47.1% YoY

Sanjivani Paranteral Board Meeting Date

Sanjivani Paranteral Ltd has scheduled a board meeting for August 14, 2026, to consider quarterly financial results, the annual report, and the upcoming Annual General Meeting.